Dr. David Palma, MD, PhD
@drdavidpalma.bsky.social
A group of Canadian teenagers designed this new board game and it's on sale now.
www.e-upgames.com - Making Board Games Great Again!
www.e-upgames.com - Making Board Games Great Again!
October 9, 2025 at 10:50 PM
A group of Canadian teenagers designed this new board game and it's on sale now.
www.e-upgames.com - Making Board Games Great Again!
www.e-upgames.com - Making Board Games Great Again!
Friendly reminder that the deadline for the Red Journal SBRT special issue is June 30. It's going to be a great issue, with more than 100 submissions already!
June 29, 2025 at 10:33 AM
Friendly reminder that the deadline for the Red Journal SBRT special issue is June 30. It's going to be a great issue, with more than 100 submissions already!
Hey #radoncs! Quadshot News is looking for financial support to continue their outstanding work. They are one of my go-to avenues to keep up in the oncology world. I get a short email every day that highlights a few key papers.
Consider a donation to keep them up and running:
quadshotnews.com
Consider a donation to keep them up and running:
quadshotnews.com
QuadShot – News
quadshotnews.com
May 23, 2025 at 4:38 PM
Hey #radoncs! Quadshot News is looking for financial support to continue their outstanding work. They are one of my go-to avenues to keep up in the oncology world. I get a short email every day that highlights a few key papers.
Consider a donation to keep them up and running:
quadshotnews.com
Consider a donation to keep them up and running:
quadshotnews.com
Interested in delivering palliative radiation using diagnostic CTs rather than a CT simulation?
See below for a discussion of some of the data.
See below for a discussion of some of the data.
Exciting news! Our Red Journal invited editorial on sim-free RT is now available! @ijrobp.bsky.social @drdavidpalma.bsky.social
Grateful for the opportunity to contribute to this discussion! Check it out here: authors.elsevier.com/c/1kYHc1Hx52... #simfreeRT #radiotherapy #palliativeRT #OpenAccess
Grateful for the opportunity to contribute to this discussion! Check it out here: authors.elsevier.com/c/1kYHc1Hx52... #simfreeRT #radiotherapy #palliativeRT #OpenAccess
February 4, 2025 at 10:04 PM
Interested in delivering palliative radiation using diagnostic CTs rather than a CT simulation?
See below for a discussion of some of the data.
See below for a discussion of some of the data.
Hey Rad Onc community!
The Red Journal @ijrobp.bsky.social is calling for papers for a new special issue:
SBRT - From Clinical Trials to Your Clinic
Details below...⬇️⬇️⬇️
The Red Journal @ijrobp.bsky.social is calling for papers for a new special issue:
SBRT - From Clinical Trials to Your Clinic
Details below...⬇️⬇️⬇️
January 14, 2025 at 6:35 PM
Hey Rad Onc community!
The Red Journal @ijrobp.bsky.social is calling for papers for a new special issue:
SBRT - From Clinical Trials to Your Clinic
Details below...⬇️⬇️⬇️
The Red Journal @ijrobp.bsky.social is calling for papers for a new special issue:
SBRT - From Clinical Trials to Your Clinic
Details below...⬇️⬇️⬇️
Reposted by Dr. David Palma, MD, PhD
Todas is HCC day!
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma
This phase 3 randomized clinical trial evaluates whether stereotactic body radiation therapy improves outcomes in patients with locally advanced hepatocellular carcinoma compared with sorafenib alone.
jamanetwork.com
December 19, 2024 at 8:57 PM
Todas is HCC day!
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
- RTOG 1112
- HCC unsuitable for or refractory to local-regional Tx (n=177)
- SBRT & Sorafenib vs Sorafenib
- After adjustment for stratification factors, improved OS after SBRT (HR 0.72)
- Median PFS improved from 5.5 to 9.2 mo (HR 0.55)
jamanetwork.com/journals/jam...
Reposted by Dr. David Palma, MD, PhD
Safe practice of spine SBRT requires high-quality data about SC dose tolerance
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...
Radiation Myelitis After Hypofractionated Spine Stereotactic Body Radiation Therapy
This cohort study characterizes the risk of radiation myelitis after spine stereotactic body radiation therapy to update the current dosimetric constraints.
jamanetwork.com
December 19, 2024 at 9:09 PM
Safe practice of spine SBRT requires high-quality data about SC dose tolerance
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...
- Cohort study 2051 pts
- 30 cases of RM, 19 of which G3 to G4
- 2a rate of G1-4 RM 1.8%
- cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years
jamanetwork.com/journals/jam...